CELLFE INC
ATLANTA, GA · Medtech · Private
Microfluidic device for mRNA transfection into T cells and lymphocytes using volume exchange and convective transfer (VECT)
- Grants
- $2.9M
- 6 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- $359K
- 1 award · Health and Human S
- #407 of 4531 in medtech
- Patents
- 27
- 4 granted · 23 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20192020202120222023202420252026
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · Efficient and scalable microfluidic gene delivery to hematopoietic stem cells to treat blood diseases | $223,810 | |
| Federal grant | Department of Health and Human Services · Phase I · Microfluidic platform for gene delivery into the T-cells | $284,735 | |
| Federal contract | Department of Health and Human Services · Topic 397 - Microfluidic Transfection Platform For Rapid Manufacturing Of Mrna Car Lymphocyte Products. | $358,930 | |
| Federal grant | Department of Health and Human Services · Phase II · Efficient and scalable microfluidic gene delivery to hematopoietic stem cells to treat blood diseases | $837,232 | |
| Federal grant | Department of Health and Human Services · Phase II · Efficient and scalable microfluidic gene delivery to hematopoietic stem cells to treat blood diseases | $843,224 | |
| Federal grant | Department of Health and Human Services · Phase I · Accelerated, scalable same-day microfluidic sequential gene editing for allogeneic cell therapy | $314,000 |
Federal grant · SBIR/STTRFederal contract · USAspending
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 404 | Opko Health, Inc. | $387K | $206M |
| 405 | DXRAY, INC. | $378K | — |
| 406 | RESHAPE LIFESCIENCES INC | $374K | $114M |
| 407 | CELLFE INC | $359K | — |
| 408 | CAPTIS DIAGNOSTICS | $355K | — |
| 409 | C-MOTION, INC. | $350K | — |
| 410 | Stereology Resource Center, Inc. | $349K | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Methods and Systems for Rapid Engineering of Resting Cellsapplication
- Systems and Methods for Sequential Microfluidic Processing of Cellsapplication
- Methods And Systems For Cell Labeling And Imaginggranted
- High-Throughput Mechanoporation for Scalable and Cost-Effective Cell Therapy Manufacturingapplication
- Methods And Systems For Mechanoporation-based High-throughput Payload Delivery Into Biological Cellsgranted
- Methods And Systems For High-throughput Cell Processinggranted
- Methods And Systems For Mechanoporation-based High-throughput Payload Delivery Into Biological Cellsgranted
- Methods And Systems For Intracellular Delivery And Products Thereofapplication
- Methods And Systems For Intracellular Deliveryapplication
- Methods And Systems For Intracellular Deliveryapplication
- Methods And Systems For Mechanoporation-based High-throughput Payload Delivery Into Biological Cellsapplication
- Methods And Systems For Cell Labeling And Imagingapplication
Regulatory activity · Medtech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.